Rebekah Leah Campbell alias The Mold-Root Marketer

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure Mast Cell Activation Syndrome.

Mast Cell Activation Syndrome

Supports

There is clinical and guideline-based evidence that targeted, multi-modal management strategies can help patients with mast cell activation syndrome and histamine-related symptoms, but these are not described in the scientific literature as generic “functional medicine protocols” applicable to any patient. Standard care for mast cell activation syndrome includes stepwise use of H1 and H2 antihistamines, mast cell stabilizers (such as cromolyn sodium), leukotriene receptor antagonists, and trigger avoidance, which resembles a structured protocol-based approach. Low-histamine diets and elimination diets are commonly used and have some supportive evidence for symptom improvement in histamine intolerance and food hypersensitivity, suggesting that dietary and lifestyle interventions can play a role in management. Narrative and review articles on food hypersensitivity and histamine intolerance highlight that individualized assessment, elimination diets, and symptom-directed pharmacologic treatment form a coherent, protocol-like management strategy, particularly in gastrointestinal manifestations, which is broadly compatible with some functional medicine practices.

Contradicts

High-quality guidelines and reviews for mast cell activation syndrome emphasize diagnostic criteria based on objective biomarkers (e.g., serum tryptase or urinary mediators) and episodic systemic symptoms, and do not endorse generic protocols that can be applied to “any patient”; instead, they recommend targeted evaluation and individualized treatment tailored to specific clinical presentations. Expert guidance for mast cell activation syndrome and mast cell disorders explicitly focuses on antihistamines, leukotriene antagonists, mast cell stabilizers, and standard anaphylaxis management, and does not support broad, non-specific functional medicine frameworks as evidence-based primary treatment. Reviews of histamine intolerance and food hypersensitivity describe limited and evolving evidence, with low-histamine diets and elimination strategies as pragmatic but not universally effective approaches; they stress that the mechanistic understanding remains incomplete, which contradicts claims that a single class of functional medicine protocols can reliably “address” these conditions in all patients. Mainstream sources also note that there are no evidence-based dietary modifications specifically recommended for mast cell activation syndrome beyond general trigger avoidance, which counters strong claims that functional medicine-style dietary protocols are established treatments. Overall, there is insufficient randomized trial or systematic review evidence showing that functional medicine protocols, as a distinct modality, are effective for mast cell activation syndrome, histamine intolerance, or “other health issues” across all patients; the evidence base instead supports condition-specific, guideline-driven management with standard pharmacologic and lifestyle measures.

Mainstream view

Mainstream medical and scientific practice views mast cell activation syndrome and histamine-related conditions as requiring careful differential diagnosis, objective evidence of mast cell mediator release, and symptom-based, guideline-aligned treatment rather than universal protocols that can be applied to any patient. For mast cell activation syndrome, major allergy and immunology work group reports recommend establishing diagnosis using clinical criteria plus laboratory evidence of mast cell activation and then using a stepwise management approach centered on H1 and H2 antihistamines, leukotriene antagonists, mast cell stabilizers, and trigger avoidance, with epinephrine and other therapies reserved for severe or anaphylactic presentations. For histamine intolerance and food hypersensitivity, mainstream reviews describe low-histamine or elimination diets, careful reintroduction, and standard pharmacologic treatment as reasonable strategies, but emphasize that the evidence base is limited and heterogenous, and that these interventions are not universally effective nor validated as generic protocols for all patients. Overall, the mainstream position is that protocol-based, multi-component management can be useful when individualized to the specific diagnosis and symptom pattern, but there is no consensus that “functional medicine protocols” as a separate category are validated, universally applicable treatments for histamine intolerance, mast cell activation syndrome, or broad unspecified health issues.

Papers listed for this claim:[1][2][3][4][5][6][7][8][9][10][11][12]

In their own wordsView sourceArchived copy

“Mast Cell Activation Syndrome”

Rule: Fla. Stat. § 460.403(9)(a), (b), (f)

See every doc bro who says they can treat or advise on MCAS and histamine intolerance

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure mold illness.

mold illness

Supports

The Jarisch-Herxheimer reaction is a well-described, acute inflammatory response occurring within about 24 hours after starting antimicrobial treatment for spirochetal infections such as syphilis, leptospirosis, Lyme disease, and relapsing fever, mediated by endotoxin-like substances and proinflammatory cytokines released from dying organisms. High-quality sources (textbook chapters, clinical reviews, and guideline-type resources) consistently define it in this infectious-disease context and not specifically for mold or mycotoxin illness. There are peer-reviewed reviews and clinical papers describing immune dysregulation and multisystem illness after exposure to water-damaged buildings, molds, and mycotoxins, including chronic inflammatory and neuroimmune symptoms, but they do not frame symptom fluctuations during treatment or detoxification as Herxheimer reactions nor provide protocol-based RCT or guideline evidence for “preventing” such reactions in mold illness. The listed articles concern vitamin C in cancer, glaucoma neuroprotection, herbal decoction for myeloma, honey for wound healing, docetaxel plus prednisone for prostate cancer, and employment outcomes after critical illness, none of which address Herxheimer reactions, mold/mycotoxin illness, or specific “healing protocols” aimed at preventing Herxheimer-type reactions, so they provide no direct supporting evidence for the influencer’s claim.

Contradicts

Mainstream medical descriptions of the Jarisch-Herxheimer reaction restrict the term to an acute, transient systemic reaction following antimicrobial therapy for certain infections, particularly spirochetal diseases, and do not include mold exposure, mycotoxin illness, or non-infectious “detox” processes in the formal definition. This contradicts the influencer’s broad use of “Herxheimer reactions” as a general die-off or detox phenomenon in mold illness. High-quality references emphasize that JHR is specifically triggered by the rapid killing of susceptible pathogens and the resulting release of endotoxin-like components rather than by mobilization of stored environmental toxins or non-microbial mold metabolites. There is currently no robust body of randomized trials, meta-analyses, or major clinical guidelines demonstrating that Herxheimer reactions occur as a defined entity in mold-related illness or that they can be reliably prevented or minimized through a standardized “healing protocol” (for example with binders, baths, supplements, or similar regimens). The listed peer-reviewed papers do not discuss Herxheimer reactions, mold illness, or protocol-based prevention of treatment-related symptom flares in this context, which underscores that the claim is not grounded in these cited literature sources.

Mainstream view

The mainstream position is that a Herxheimer (Jarisch-Herxheimer) reaction is a specific, acute, self-limited reaction that occurs shortly after initiating antimicrobial therapy for certain infections, most characteristically spirochetal diseases, due to the release of microbial components and the ensuing cytokine surge. Symptom worsening during treatment or detox protocols in mold or mycotoxin illness is sometimes described informally in alternative or integrative circles as “Herx” or “die-off,” but this usage is not supported by strong clinical trial evidence and is not incorporated into major infectious disease, toxicology, or allergy guidelines as a recognized Jarisch-Herxheimer phenomenon. For mold and mycotoxin-related illness, mainstream management focuses on exposure reduction, symptomatic treatment, and, when necessary, evidence-based interventions for allergic disease, infection, or established toxic effects; major guidelines do not describe a standard “healing protocol” designed to prevent Herxheimer reactions in this setting. The specific papers listed are unrelated to mold illness or Herxheimer reactions and thus do not inform or support the influencer’s assertion.

Papers listed for this claim:[13][14][15][16][17]

In their own wordsView sourceArchived copy

“mold illness”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Mold illness and CIRS

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure Hashimoto’s Thyroiditis.

Hashimoto’s Thyroiditis

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“Hashimoto’s Thyroiditis”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Thyroid disease and Hashimoto

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to advertise Functional medicine protocols can be applied to any patient and address histamine intolerance, mast cell activation syndrome, and other health issues. as within their scope of practice.

Functional medicine protocols can be applied to any patient and address histamine intolerance, mast cell activation syndrome, and other health issues.

Supports

There is clinical and guideline-based evidence that targeted, multi-modal management strategies can help patients with mast cell activation syndrome and histamine-related symptoms, but these are not described in the scientific literature as generic “functional medicine protocols” applicable to any patient. Standard care for mast cell activation syndrome includes stepwise use of H1 and H2 antihistamines, mast cell stabilizers (such as cromolyn sodium), leukotriene receptor antagonists, and trigger avoidance, which resembles a structured protocol-based approach. Low-histamine diets and elimination diets are commonly used and have some supportive evidence for symptom improvement in histamine intolerance and food hypersensitivity, suggesting that dietary and lifestyle interventions can play a role in management. Narrative and review articles on food hypersensitivity and histamine intolerance highlight that individualized assessment, elimination diets, and symptom-directed pharmacologic treatment form a coherent, protocol-like management strategy, particularly in gastrointestinal manifestations, which is broadly compatible with some functional medicine practices.

Contradicts

High-quality guidelines and reviews for mast cell activation syndrome emphasize diagnostic criteria based on objective biomarkers (e.g., serum tryptase or urinary mediators) and episodic systemic symptoms, and do not endorse generic protocols that can be applied to “any patient”; instead, they recommend targeted evaluation and individualized treatment tailored to specific clinical presentations. Expert guidance for mast cell activation syndrome and mast cell disorders explicitly focuses on antihistamines, leukotriene antagonists, mast cell stabilizers, and standard anaphylaxis management, and does not support broad, non-specific functional medicine frameworks as evidence-based primary treatment. Reviews of histamine intolerance and food hypersensitivity describe limited and evolving evidence, with low-histamine diets and elimination strategies as pragmatic but not universally effective approaches; they stress that the mechanistic understanding remains incomplete, which contradicts claims that a single class of functional medicine protocols can reliably “address” these conditions in all patients. Mainstream sources also note that there are no evidence-based dietary modifications specifically recommended for mast cell activation syndrome beyond general trigger avoidance, which counters strong claims that functional medicine-style dietary protocols are established treatments. Overall, there is insufficient randomized trial or systematic review evidence showing that functional medicine protocols, as a distinct modality, are effective for mast cell activation syndrome, histamine intolerance, or “other health issues” across all patients; the evidence base instead supports condition-specific, guideline-driven management with standard pharmacologic and lifestyle measures.

Mainstream view

Mainstream medical and scientific practice views mast cell activation syndrome and histamine-related conditions as requiring careful differential diagnosis, objective evidence of mast cell mediator release, and symptom-based, guideline-aligned treatment rather than universal protocols that can be applied to any patient. For mast cell activation syndrome, major allergy and immunology work group reports recommend establishing diagnosis using clinical criteria plus laboratory evidence of mast cell activation and then using a stepwise management approach centered on H1 and H2 antihistamines, leukotriene antagonists, mast cell stabilizers, and trigger avoidance, with epinephrine and other therapies reserved for severe or anaphylactic presentations. For histamine intolerance and food hypersensitivity, mainstream reviews describe low-histamine or elimination diets, careful reintroduction, and standard pharmacologic treatment as reasonable strategies, but emphasize that the evidence base is limited and heterogenous, and that these interventions are not universally effective nor validated as generic protocols for all patients. Overall, the mainstream position is that protocol-based, multi-component management can be useful when individualized to the specific diagnosis and symptom pattern, but there is no consensus that “functional medicine protocols” as a separate category are validated, universally applicable treatments for histamine intolerance, mast cell activation syndrome, or broad unspecified health issues.

Papers listed for this claim:[1][2][3][4][5][6][7][8][9][10][11][12]

In their own wordsView sourceArchived copy

“all of these protocols can be applied to any patient”

Rule: Fla. Stat. § 460.403(9)(c)

See every doc bro who says they can treat or advise on MCAS and histamine intolerance

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure Mycotoxins cause endocrine disruption, gut dysbiosis, leaky gut, inflammation, and immune dysregulation..

Mycotoxins cause endocrine disruption, gut dysbiosis, leaky gut, inflammation, and immune dysregulation.

Supports

There is moderate to strong evidence that some mycotoxins can act as endocrine disruptors, particularly affecting reproductive hormones and fertility. Clinical and toxicological reviews report that exposure to several mycotoxins correlates with precocious puberty, reduced fertility, and increased hormone‑related cancers in humans, indicating endocrine disruption of the reproductive axis. Cyclic depsipeptide mycotoxins and zearalenone derivatives show endocrine‑disrupting effects via inhibition of steroidogenesis and interaction with nuclear hormone receptors, consistent with direct interference in endocrine signaling. A recent clinical review concludes that mycotoxins are potent natural substances with widespread negative effects on endocrine system functioning, leading to reproductive problems in humans. There is high‑quality evidence (several comprehensive reviews and emerging systematic reviews) that dietary mycotoxins disrupt gut microbiota composition, consistent with gut dysbiosis. Reviews on dietary mycotoxins and gut microbiome demonstrate modulation of microbial composition down to species level and disruption of gut microbiota balance, with suppression of beneficial taxa (e.g., Lactobacillus, Bifidobacterium) and expansion of pro‑inflammatory genera. Recent reviews focusing on microbiome–mycotoxin interactions and emerging mycotoxins describe significant disruption of microbiome composition and functional stability, including altered short‑chain fatty acid production and bile acid metabolism, which are hallmarks of dysbiosis. A scoping review of mycotoxins, gut microbiota alterations, and liver disease similarly reports consistent depletion of barrier‑supporting, SCFA‑producing taxa and expansion of pro‑inflammatory genera, indicating dysbiosis in animal models. There is substantial evidence that mycotoxins damage intestinal barrier integrity (a mechanistic correlate of "leaky gut") and induce local and systemic inflammation. Reviews of dietary mycotoxins and gut microbiome emphasize that mycotoxins impair tight junction proteins, compromise intestinal barrier function, and increase intestinal permeability, allowing translocation of toxins and endotoxin. Mechanistic and multi‑omics reviews show that mycotoxins disrupt epithelial barrier integrity and mucosal repair, reducing SCFA availability and undermining mucosal health, which promotes inflammatory conditions. Experimental work with specific mycotoxins (e.g., T‑2 toxin in chicks) demonstrates intestinal damage together with dysregulated metabolism, redox homeostasis, inflammation, and apoptosis. Animal studies of aflatoxin B1 and other mycotoxins report neuroinflammation and systemic inflammatory responses. A multi‑omics study of zearalenone shows ovarian and intestinal inflammation mediated by TNF‑α. Altogether, these support a causal link between mycotoxin exposure, barrier damage (increased permeability) and inflammation. Immune dysregulation is also supported, although much of the evidence is preclinical. Reviews of mycotoxins and gut health show that disruption of gut microbiota and barrier function dysregulates local intestinal immune responses, which may lead to systemic toxicity and chronic mycotoxicosis. Mechanistic work on deoxynivalenol‑induced spleen toxicity in mice shows inflammation, ER stress, altered macrophage polarization, and dysregulated long non‑coding RNA expression, all indicative of immune and inflammatory pathway perturbation. Narrative reviews on mycotoxins and microbial disruption report suppression of immune function and increased susceptibility to infection, consistent with immune dysregulation. The scoping review on gut–liver–hypothalamus axis dysfunction in animals notes that mycotoxin‑driven dysbiosis and increased intestinal permeability facilitate endotoxin‑driven hepatic oxidative stress and inflammation, further supporting systemic immune and inflammatory consequences. Overall, high‑quality reviews and experimental studies support that certain mycotoxins can cause endocrine disruption (mainly reproductive), gut dysbiosis, intestinal barrier damage with increased permeability, inflammation, and immune pathway disturbances in exposed animals, with growing but more limited human data linking endocrine and possibly immune effects.

Contradicts

Although multiple reviews and experimental studies support components of the claim, the evidence is not uniform across all mycotoxins, exposure levels, and health outcomes. Many of the strongest data on endocrine disruption, gut dys

Papers listed for this claim:[18][19][20][21][22][23][24][25][26][27][28][29]

In their own wordsView sourceArchived copy

“The science behind mold-induced dysbiosis and why it keeps driving inflammation, leaky gut, and immune dysregulation”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Mold illness and CIRS

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to advertise Mold illness traps the body in a cell danger response. as within their scope of practice.

Mold illness traps the body in a cell danger response.

Supports

The peer‑reviewed perspective on the cell danger response (CDR) describes it as a universal, conserved metabolic and signaling response to environmental threat or injury, regulated by mitochondria and involving changes in cellular bioenergetics and communication. This framework explicitly proposes that many chronic illnesses may involve cells that remain abnormally in one of several CDR stages instead of completing the healing cycle, leading to persistent hypometabolic and inflammatory states. The CDR concept also notes that chemical, physical, and microbial threats can trigger this response, and incomplete resolution can contribute to chronic disease and aging by creating mosaics of cells stuck in CDR stages. These papers therefore support a general idea that environmental insults can place cells into a danger-response state and that failure to exit this state may be linked to chronic illness.

Papers listed for this claim:[30][31][32][33][34][35][36][37][38][39][40][41]

In their own wordsView sourceArchived copy

“How Mold Traps Your Body in Danger: The Secrets of Cell Danger Response”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Mold illness and CIRS

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure Natural strategies can improve thyroid function and treat or relieve Hashimoto’s-related symptoms..

Natural strategies can improve thyroid function and treat or relieve Hashimoto’s-related symptoms.

Supports

High-quality evidence supports that some natural or non-pharmacologic strategies can beneficially influence aspects of Hashimoto’s thyroiditis and thyroid function, mainly as adjuncts to standard levothyroxine therapy rather than standalone cures. The Lancet review on hypothyroidism emphasizes that primary treatment is synthetic levothyroxine but notes that iodine status, selenium, and overall nutritional state influence thyroid hormone synthesis and metabolism, implying a role for targeted nutrition alongside pharmacologic therapy. The comprehensive review on Hashimoto’s thyroiditis describes the disease as an autoimmune process with environmental and nutritional modifiers (such as iodine intake, selenium, and vitamin D), and discusses interest in diet and micronutrient optimization as part of therapeutic strategies, although the core treatment of hypothyroidism remains levothyroxine. Systematic review data show that specific nutritional interventions can improve selected biochemical markers and patient-reported outcomes in Hashimoto’s. The systematic review on nutritional intervention in Hashimoto’s thyroiditis summarizes prospective studies where dietary changes (e.g., gluten-free diet in celiac disease, reduction of ultra-processed foods, anti-inflammatory patterns) and supplementation (selenium, myo‑inositol, vitamin D) were associated with reductions in thyroid antibody titers and sometimes improved well-being or quality of life. The narrative review on nutritional management of Hashimoto’s thyroiditis describes an anti-inflammatory, nutrient-dense diet; adequate protein; appropriate iodine intake; and selected supplements (e.g., selenium, vitamin D, omega‑3) as potentially beneficial for immune modulation and symptom relief when used with standard care. Multiple meta-analyses and systematic reviews support selenium supplementation as one “natural” adjunct that can improve some Hashimoto-related parameters. A systematic review and meta-analysis of selenium in Hashimoto’s thyroiditis found that 3–6 months of selenium supplementation led to significantly lower thyroid peroxidase antibodies (TPOAb) and a higher likelihood of improved mood and well-being in patients already on levothyroxine. Newer meta-analytic evidence including more cohorts similarly reports that selenium supplementation, particularly selenomethionine, reduces TPOAb and TSH levels and improves subjective well-being or mood in Hashimoto’s patients, with moderate-certainty evidence and no major safety concerns at typical doses. Another meta-analysis found selenium lowered TSH in patients not on thyroid hormone replacement and lowered TPOAb and oxidative stress markers (malondialdehyde), supporting a disease-modifying effect rather than simple symptomatic relief. Emerging RCT and protocol data suggest that structured diet plus probiotics may improve quality of life and nutritional status in Hashimoto’s. A protocol and subsequent early reports of a double-blind trial in women with autoimmune hypothyroidism describe a 12-week intervention using personalized nutrition education plus probiotic Lactiplantibacillus plantarum 299v versus nutrition education plus placebo, aiming to improve diet quality, anthropometrics, blood pressure, and anti-TPO titers; the rationale is that diet and microbiota modulation can relieve symptoms and improve life quality in Hashimoto’s. An RCT of a “rational, health-promoting” diet supplemented with Lp299v suggests that the combination enhances benefits of nutritional intervention on eating habits, nutritional status, health, and quality of life in HT patients, indicating that these non-pharmacologic strategies can relieve Hashimoto-related symptoms even though they do not replace hormone therapy. Reviews on the thyroid–gut axis further support a plausible mechanism by which diet and microbiota-targeted strategies could influence thyroid function and autoimmunity. The thyroid–gut-axis review discusses how gut microbiota composition, intestinal permeability, micronutrient absorption (especially iodine, selenium, iron), and immune signaling can modulate thyroid hormone metabolism and autoimmune thyroiditis; it concludes that dietary patterns and probiotics may have a supportive role in maintaining thyroid health and potentially alleviating autoimmune thyroid disease manifestations. Taken together, these sources support the narrow version of the influencer’s claim: some natural strategies (nutritional optimization, selected supplements such as selenium, and microbiota-focused interventions) can improve certain aspects of thyroid function and relieve Hashimoto’s-related symptoms when used as adjuncts to evidence-based medical care, particularly levothyroxine.

Papers listed for this claim:[42][43][44][45][46][47][48][49][50][51][52][53]

In their own wordsView sourceArchived copy

“Natural Ways to Improve Thyroid Function, Boost Energy, and Regain Your Health”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Thyroid disease and Hashimoto

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to advertise Vagus nerve toning helps patients recover from mold illness. as within their scope of practice.

Vagus nerve toning helps patients recover from mold illness.

Supports

The listed papers are unrelated to mold-related illness or vagus nerve interventions, so they do not directly support the claim that vagus nerve toning helps patients recover from mold illness. High-quality evidence does show that invasive and non‑invasive vagus nerve stimulation can modulate inflammatory pathways and may improve outcomes in some inflammatory and autoimmune conditions (e.g., rheumatoid arthritis, inflammatory bowel disease, sepsis, chronic pain, metabolic syndrome, vascular cognitive impairment). Systematic and narrative reviews of vagus nerve stimulation report anti‑inflammatory effects via the cholinergic anti‑inflammatory pathway, along with clinical benefits in epilepsy, depression, and selected inflammatory diseases, though effects on specific cytokines are often modest or inconsistent. Small randomized or pilot trials of transcutaneous auricular vagus nerve stimulation show benefits on stress responses (e.g., cortisol), depressive symptoms, and markers of inflammation in selected populations (IBD, chronic pain, HIV with depression), suggesting that modulating vagal tone can influence neuroimmune and stress physiology. Preclinical models demonstrate that vagus nerve stimulation can reduce inflammatory cytokines and improve outcomes across several inflammatory disease models, supporting a plausible biological mechanism for using vagal modulation in chronic inflammatory states.

Contradicts

There is no direct high‑quality evidence (RCTs, meta‑analyses, or guidelines) linking vagus nerve toning or vagus nerve stimulation to improved clinical outcomes specifically in mold-related illness or chronic inflammatory response syndrome due to mold exposure. A recent systematic review and meta‑analysis of vagus nerve stimulation in humans found no consistent evidence that VNS produces robust, reproducible anti‑inflammatory effects on key cytokines (TNF‑α, IL‑6, IL‑1β, IL‑10) across diverse populations, indicating that claims of broad anti‑inflammatory benefits are currently not strongly substantiated. Some clinical intervention studies aimed at modulating vagus nerve activity (including in chronic inflammatory conditions such as dialysis patients) have failed to show significant changes in key inflammatory markers (e.g., CRP, IL‑1, IL‑10) after weeks of VNS, highlighting that the anti‑inflammatory impact in humans can be limited or variable. Existing reviews emphasize that although VNS is FDA‑approved for epilepsy and depression and shows promise for selected inflammatory conditions, the mechanisms and clinical efficacy are still under investigation and not generalizable to all chronic inflammatory or toxin‑related syndromes. Major clinical guidelines for mold exposure, mycotoxin-related illness, or chronic inflammatory response syndrome do not currently recommend vagus nerve toning or VNS as standard treatment, and focus instead on exposure elimination, environmental remediation, symptomatic management, and evidence‑based pharmacologic and rehabilitative strategies.

Mainstream view

Mainstream medicine accepts that the vagus nerve plays a central role in autonomic regulation and the cholinergic anti‑inflammatory pathway, and recognizes vagus nerve stimulation as an established therapy for refractory epilepsy and treatment‑resistant depression, with emerging but still experimental use in certain inflammatory and pain conditions. Current mainstream scientific views consider vagus nerve modulation (including invasive VNS and non‑invasive approaches such as transcutaneous auricular VNS) as promising but investigational for broader inflammatory and immune‑mediated disorders, requiring more high‑quality, condition‑specific trials to define efficacy, safety, and indication. Mold‑related illness and chronic inflammatory response syndrome are managed primarily by reducing or eliminating exposure, environmental remediation, and treating established organ involvement; autonomic and vagal‑tone oriented therapies may be used by some clinicians as adjunctive

Papers listed for this claim:[54][55][56][57][58][59][60][61][62][63][64][65]

In their own wordsView sourceArchived copy

“When helping my patients recover from mold illness, I zero in on the big hitters”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Mold illness and CIRS

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to advertise Cleanest Retail Picks for MCAS as within their scope of practice.

Cleanest Retail Picks for MCAS

Supports

The claim appears to suggest that a curated list of “cleanest retail picks” (presumably over‑the‑counter products or supplements) constitutes a licensed treatment approach for mast cell activation syndrome (MCAS). There is high‑quality evidence and guideline‑level consensus that pharmacologic treatments such as H1 and H2 antihistamines, leukotriene receptor antagonists, mast cell stabilizers (e.g., cromolyn sodium, ketotifen), prostaglandin blockers (aspirin), anti‑IgE monoclonal antibodies (omalizumab), and epinephrine for acute episodes are effective and appropriate components of MCAS management. Major professional society guidance (e.g., AAAAI work group reports and other expert reviews) and reputable clinical resources endorse a stepwise, evidence‑based protocol centered on trigger avoidance plus these medications, many of which are available as standard OTC or prescription drugs rather than influencer‑curated retail products. These sources therefore support the general idea that certain common retail medications (especially non‑sedating H1 antihistamines and H2 blockers) can be part of appropriate MCAS treatment when used under medical supervision, but they do not support an influencer‑branded “cleanest retail picks” list as a distinct licensed therapy model.

Contradicts

No high‑quality evidence, randomized trials, systematic reviews, or major guidelines recognize an influencer‑curated “cleanest retail picks” list as a licensed treatment of MCAS. The core MCAS literature instead emphasizes standardized pharmacologic classes (H1/H2 antihistamines, leukotriene antagonists, mast cell stabilizers, omalizumab, aspirin, epinephrine) within a medically supervised, stepwise algorithm, not brand‑ or influencer‑specific retail curation. Guidelines and expert reviews stress diagnostic rigor and demonstration of response to MC‑targeted therapy, and they caution that MCAS is often over‑suspected and mis‑labeled, underscoring the need for formal evaluation rather than self‑directed treatment based on non‑medical influencer lists. There is also no regulatory or licensing framework that treats a list of “clean” products as a licensed medical treatment; licensing in the literature refers to clinically tested and regulator‑approved drugs or biologics, such as monoclonal antibodies, not retail product lists. Thus, the notion that an influencer’s “cleanest retail picks” constitute licensed treatment is not supported and is contradicted by mainstream evidence‑based practice, which requires physician‑guided selection of agents and dosing rather than informal retail curation.

Mainstream view

The mainstream medical position is that mast cell activation syndrome should be diagnosed using established criteria (clinical symptoms involving at least two organ systems, objective biomarker changes such as increased tryptase or mediator metabolites, and documented response to mast‑cell‑directed treatment), followed by evidence‑based management under professional supervision. Standard care focuses on trigger identification and avoidance, lifelong access to epinephrine for anaphylaxis, and a stepwise pharmacologic regimen starting with second‑generation H1 antihistamines plus H2 antihistamines, then adding leukotriene receptor antagonists, mast cell stabilizers, prostaglandin blockers (e.g., aspirin when appropriate), and omalizumab or other advanced agents for refractory cases. Some of these medications may be available as OTC or retail products, but mainstream guidance specifies their use by drug class, dose, and indication rather than by influencer‑curated brands or “cleanest picks,” and no guideline treats such curated retail lists as licensed therapeutic interventions.

Papers listed for this claim:[66][67][68][69][70][71][72][73][74][75][12][11]

In their own wordsView sourceArchived copy

“Cleanest Retail Picks for MCAS”

Rule: Fla. Stat. § 460.403(9)(c)

See every doc bro who says they can treat or advise on MCAS and histamine intolerance

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure The Perimenopause and Histamine Guide.

The Perimenopause and Histamine Guide

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“The Perimenopause and Histamine Guide”

Rule: Fla. Stat. § 460.403(9)(c)

See every doc bro who says they can treat or advise on Menopause

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure Perimenopause and Histamine Quiz.

Perimenopause and Histamine Quiz

No specific health claims of theirs were cross-checked against the literature.

In their own wordsView sourceArchived copy

“Perimenopause and Histamine Quiz”

Rule: Fla. Stat. § 460.403(9)(c)

See every doc bro who says they can treat or advise on Menopause

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure Histamine Intolerance.

Histamine Intolerance

Supports

There is clinical and guideline-based evidence that targeted, multi-modal management strategies can help patients with mast cell activation syndrome and histamine-related symptoms, but these are not described in the scientific literature as generic “functional medicine protocols” applicable to any patient. Standard care for mast cell activation syndrome includes stepwise use of H1 and H2 antihistamines, mast cell stabilizers (such as cromolyn sodium), leukotriene receptor antagonists, and trigger avoidance, which resembles a structured protocol-based approach. Low-histamine diets and elimination diets are commonly used and have some supportive evidence for symptom improvement in histamine intolerance and food hypersensitivity, suggesting that dietary and lifestyle interventions can play a role in management. Narrative and review articles on food hypersensitivity and histamine intolerance highlight that individualized assessment, elimination diets, and symptom-directed pharmacologic treatment form a coherent, protocol-like management strategy, particularly in gastrointestinal manifestations, which is broadly compatible with some functional medicine practices.

Contradicts

High-quality guidelines and reviews for mast cell activation syndrome emphasize diagnostic criteria based on objective biomarkers (e.g., serum tryptase or urinary mediators) and episodic systemic symptoms, and do not endorse generic protocols that can be applied to “any patient”; instead, they recommend targeted evaluation and individualized treatment tailored to specific clinical presentations. Expert guidance for mast cell activation syndrome and mast cell disorders explicitly focuses on antihistamines, leukotriene antagonists, mast cell stabilizers, and standard anaphylaxis management, and does not support broad, non-specific functional medicine frameworks as evidence-based primary treatment. Reviews of histamine intolerance and food hypersensitivity describe limited and evolving evidence, with low-histamine diets and elimination strategies as pragmatic but not universally effective approaches; they stress that the mechanistic understanding remains incomplete, which contradicts claims that a single class of functional medicine protocols can reliably “address” these conditions in all patients. Mainstream sources also note that there are no evidence-based dietary modifications specifically recommended for mast cell activation syndrome beyond general trigger avoidance, which counters strong claims that functional medicine-style dietary protocols are established treatments. Overall, there is insufficient randomized trial or systematic review evidence showing that functional medicine protocols, as a distinct modality, are effective for mast cell activation syndrome, histamine intolerance, or “other health issues” across all patients; the evidence base instead supports condition-specific, guideline-driven management with standard pharmacologic and lifestyle measures.

Mainstream view

Mainstream medical and scientific practice views mast cell activation syndrome and histamine-related conditions as requiring careful differential diagnosis, objective evidence of mast cell mediator release, and symptom-based, guideline-aligned treatment rather than universal protocols that can be applied to any patient. For mast cell activation syndrome, major allergy and immunology work group reports recommend establishing diagnosis using clinical criteria plus laboratory evidence of mast cell activation and then using a stepwise management approach centered on H1 and H2 antihistamines, leukotriene antagonists, mast cell stabilizers, and trigger avoidance, with epinephrine and other therapies reserved for severe or anaphylactic presentations. For histamine intolerance and food hypersensitivity, mainstream reviews describe low-histamine or elimination diets, careful reintroduction, and standard pharmacologic treatment as reasonable strategies, but emphasize that the evidence base is limited and heterogenous, and that these interventions are not universally effective nor validated as generic protocols for all patients. Overall, the mainstream position is that protocol-based, multi-component management can be useful when individualized to the specific diagnosis and symptom pattern, but there is no consensus that “functional medicine protocols” as a separate category are validated, universally applicable treatments for histamine intolerance, mast cell activation syndrome, or broad unspecified health issues.

Papers listed for this claim:[1][2][3][4][5][6][7][8][9][10][11][12]

In their own wordsView sourceArchived copy

“Histamine Intolerance”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on MCAS and histamine intolerance

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to advertise Functional medicine can identify the root cause of complicated health issues through individualized assessment. as within their scope of practice.

Functional medicine can identify the root cause of complicated health issues through individualized assessment.

Supports

The core methods promoted in functional medicine—extended history-taking, consideration of lifestyle and social determinants of health, and systems-oriented thinking—do overlap with mainstream trends toward more individualized, etiologic assessment for complex chronic illness, such as precision medicine and comprehensive guideline-based evaluations for specific conditions. There is some emerging outcomes data suggesting that a functional-medicine-style model of care can be associated with short-term improvements in patient-reported quality of life compared to conventional primary care, although these data are observational and not focused on objective disease outcomes. Functional medicine literature emphasizes structured "root cause" frameworks (e.g., functional medicine matrix, 5R gastrointestinal model, SDOH mapping) intended to organize individualized assessment across multiple domains; these frameworks are conceptually aligned with understanding multifactorial etiologies but are largely supported by narrative reviews, case series, and expert opinion rather than high-level comparative trials. Mainstream evidence in other domains (e.g., metabolomics for diabetic retinopathy risk prediction, comprehensive algorithms for PAH screening in systemic sclerosis) shows that more granular, individualized investigations can indeed improve identification of underlying risk factors or pathophysiology, supporting the general idea that detailed assessment can clarify contributors to complex disease without specifically validating the proprietary functional medicine model.

Contradicts

High-quality evidence specifically validating "functional medicine" as a unique clinical model that reliably identifies the root cause of complicated health issues is limited; published critiques note an inadequate evidence base, reliance on unproven suppositions, and a lack of randomized controlled trials or large prospective studies testing whether functional medicine more accurately identifies etiologies or improves hard clinical outcomes compared with standard care. Analyses of functional medicine practice patterns report heavy use of non-guideline-supported and often unnecessary laboratory testing, with the majority of results normal and substantially higher testing costs, suggesting that the style of individualized assessment may increase false positives and resource use without demonstrable gains in diagnostic accuracy. The main Cleveland Clinic-type outcome studies cited by functional medicine advocates measure patient-reported quality of life and are retrospective, short-term, and subject to confounding (e.g., longer visits, lifestyle counseling), and they do not show that functional medicine uniquely identifies root causes or outperforms evidence-based diagnostic algorithms for specific complex diseases. Major guidelines for complex conditions (e.g., functional hypothalamic amenorrhea, pediatric malnutrition, systemic sclerosis–associated pulmonary arterial hypertension) specify structured, evidence-based diagnostic criteria and workups but do not recommend functional medicine as a distinct approach or endorse its proprietary testing panels or frameworks as superior methods for root-cause identification. Overall, the claim that functional medicine "can identify the root cause" of complicated health issues suggests a level of proven diagnostic superiority and generality across conditions that is not supported by current high-level evidence; available data are largely conceptual, anecdotal, or based on small case series, not robust comparative trials or systematic reviews.

Mainstream view

Mainstream medicine accepts that many complicated health issues are multifactorial and increasingly endorses more individualized, etiologically informed assessment using validated tools—such as guideline-based diagnostic algorithms, evidence-based lab utilization, advanced imaging, and, in selected areas, omics and precision medicine—while insisting that diagnostic and therapeutic strategies be supported by randomized trials, systematic reviews, and robust observational data. For specific complex conditions, mainstream practice relies on condition-specific guidelines (e.g., endocrine and rheumatology societies, nutrition societies) that define evidence-based criteria and investigations for identifying underlying causes, and these guidelines do not position functional medicine as a distinct or preferred pathway. The prevailing view in academic and guideline-driven medicine is that elements emphasized by functional medicine—holistic lifestyle counseling, attention to social determinants of health, and thorough history-taking—are valuable when integrated into evidence-based care, but the broader branded "functional medicine" model, including its root-cause matrices and frequent use of nonstandard testing, lacks sufficient high-quality evidence to claim superior ability to identify root causes of complex disease across the board. Mainstream experts generally regard functional medicine as a heterogeneous movement in which some practices are aligned with evidence-based lifestyle and preventive medicine, while others (especially extensive nonvalidated testing and

Papers listed for this claim:[76][77][78][79][80][81][82][83][84][85][86][87]

In their own wordsView sourceArchived copy

“get to the root of your issue”

Rule: Fla. Stat. § 460.403(9)(a), (f)

Rebekah Leah Campbell is not licensed or approved by Florida Board of Chiropractic Medicine to diagnose, treat, or cure The practice can help eliminate headaches, migraines, digestive problems, fatigue, anxiety, menstrual issues, bladder problems, and unexplained symptoms..

The practice can help eliminate headaches, migraines, digestive problems, fatigue, anxiety, menstrual issues, bladder problems, and unexplained symptoms.

Supports

The influencer’s claim is extremely broad and nonspecific about what “the practice” is, so it cannot be directly matched to a defined intervention such as cognitive behavioral therapy, biofeedback, or a particular mind‑body technique. However, there is some high‑quality evidence that certain psychological and mind‑body therapies can reduce specific symptoms within this list, particularly headaches and migraines. A Cochrane review on psychological therapies for chronic and recurrent pain in children and adolescents concluded that cognitive and behavioral interventions reduce headache pain and disability, especially for headache conditions. Narrative and systematic reviews of psychological and mind‑body approaches to migraine (e.g., relaxation, biofeedback, cognitive behavioral therapy, mindfulness‑based approaches) report clinically meaningful reductions in headache frequency and impact in many patients, often comparable to preventive medications, although this is based on multiple RCTs and meta‑analyses not individually listed here. Mind‑body and behavioral treatments have moderate evidence for improving anxiety symptoms and stress‑related somatic complaints, which can secondarily improve fatigue and some functional digestive symptoms in conditions like functional abdominal pain or irritable bowel syndrome, but this pertains to specific, well‑defined therapies rather than a generic “practice.”

Contradicts

The listed papers focus on mechanisms and classifications of headache and migraine and do not support the idea that a single generic practice can eliminate a wide spectrum of conditions such as headaches, migraines, digestive problems, fatigue, anxiety, menstrual issues, bladder problems, and unexplained symptoms. These sources emphasize complex, multifactorial pathophysiology of headache and migraine (including nociplastic, vascular, hormonal, and neurologic factors) rather than cure by a single non‑specific intervention. None of the listed articles claims complete elimination of migraines or headaches, only reduction in frequency or severity when discussing psychological or behavioral strategies, and the majority do not discuss digestive, menstrual, bladder, or global “unexplained” symptoms at all. High‑quality evidence for psychological or mind‑body therapies in menstrual disorders, bladder problems, and many types of “unexplained symptoms” is limited, condition‑specific, and generally shows partial symptom relief rather than cure; there is no robust evidence that a single practice eliminates all of these diverse conditions. Overall, the breadth and absoluteness of the influencer’s claim (“eliminate” a very wide range of unrelated conditions) is not supported by the available evidence, and it overgeneralizes from more modest, condition‑specific findings.

Mainstream view

Mainstream medical and scientific opinion is that headaches, migraines, digestive problems, fatigue, anxiety, menstrual issues, bladder problems, and unexplained symptoms are heterogeneous conditions with varied and often complex causes, requiring targeted, condition‑specific assessment and management. Evidence‑based guidelines support the use of psychological and mind‑body therapies as adjuncts for some of these problems (especially headaches/migraine and anxiety, and to a lesser extent some functional gastrointestinal syndromes), generally to reduce symptom burden and improve quality of life, not to eliminate disease. Psychological therapies are recognized as one useful component within multimodal care for chronic pain and headache in children and adolescents, but they are not considered curative for all related or unrelated systemic symptoms. For menstrual, bladder, and many medically unexplained symptoms, standard care typically includes medical evaluation for underlying pathology plus condition‑specific pharmacologic, behavioral, and sometimes psychological treatments; no major guideline endorses a single generic practice as capable of eliminating this entire range of conditions.

Papers listed for this claim:[88][89][90][91][92][93][94][95][96][97][98][99]

In their own wordsView sourceArchived copy

“We can help you come up with a plan to eliminate frequent headaches, migraines, digestive problems, fatigue, anxiety, menstrual issues, bladder problems, Or other uncomfortable, unexplained symptoms.”

Rule: Fla. Stat. § 460.403(9)(a), (f)

See every doc bro who says they can treat or advise on Anxiety